If you have Type 1 diabetes, your entire day can be spent treating your condition. Over the past few decades, technology has advanced significantly, making life as a Type 1 diabetic easier than ever before. The FDA approval of a new medical device called the artificial pancreas in September 2016 will continue this trend. Derek Rapp, President and CEO for the Juvenile Diabetes Research Foundation (JDRF) says that the artificial pancreas “is a historical achievement for JDRF and the entire T1D community. After years of laying the ground work, this life-changing breakthrough is a true testament to the reason JDRF exists, which is to accelerate ways to cure, prevent, and treat this disease.”
It is a common digestive disorder. Approximately sixty million people among the total population of the USA experience the symptoms monthly.
Scientists continue to work on better ways to design, conduct and evaluate non-randomized (., observational) studies to assess how well flu vaccines work. CDC has been working with researchers at universities and hospitals since the 2003-2004 flu season to estimate how well flu vaccine works through observational studies using laboratory-confirmed flu as the outcome. These studies currently use a very accurate and sensitive laboratory test known as RT-PCR (reverse transcription polymerase chain reaction) to confirm medically-attended flu virus infections as a specific outcome. CDC’s studies are conducted in five sites across the United States to gather more representative data. To assess how well the vaccine works across different age groups, CDC’s studies of flu vaccine effects have included all people aged 6 months and older recommended for an annual flu vaccination. Similar studies are being done in Australia, Canada and Europe. More recently, CDC has set up a second network the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN) that looks at how well flu vaccine protects against flu-related hospitalization among adults aged 18 and older.